| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 189 4 |
| Ultima descărcare din IBN: 2023-09-13 15:31 |
 SM ISO690:2012GUNTHER, Gunar, VAN LETH, Frank, ALEXANDRU, Sofia, NOI, Autori, BARBUŢĂ, Raisa, KRUDU, V., CERNENCO, Ilie, DUBCEAC, Vera. Multidrug-resistant tuberculosis in Europe, 2010-2011. In: Emerging Infectious Diseases, 2015, vol. 21, nr. 3, pp. 409-416. ISSN 1080-6040. DOI: https://doi.org/10.3201/eid2103.141343 |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
  Emerging Infectious Diseases |
|
| Volumul 21, Numărul 3 / 2015 / ISSN 1080-6040 /ISSNe 1080-6059 | |
|
|
| DOI:https://doi.org/10.3201/eid2103.141343 | |
| Pag. 409-416 | |
 Descarcă PDF |
|
| Rezumat | |
Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to >1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fuoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe. |
|
| Cuvinte-cheie adult, Antitubercular Agents, comorbidity, Cross-Sectional Studies, Europe, female, history, 21st Century, Humans, incidence, Male, Microbial Sensitivity Tests, middle aged, Mycobacterium tuberculosis, Population Surveillance, risk factors, tuberculosis, Multidrug-Resistant |
|
|
|
|
|
